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ABSTRACT 
   
Objectives: There is a need to improve the assessment of emotional functioning (EF). In the 
international ACTION trial involving patients with advanced cancer, EF was assessed by a 
customized 10-item short-form (EF10). The EF10 is based on the European Organisation for 
Research and Treatment of Cancer (EORTC) EF item bank and has the potential for greater 
precision than the common EORTC QLQ-C30 4-item scale (EF4). We assessed the relative 
validity (RV) of EF10 compared to EF4. 
Methods: Patients from Belgium, Denmark, Italy, Netherlands, Slovenia and United Kingdom 
completed EF10 and EF4, and provided data on generic quality of life, coping, self-efficacy and 
personal characteristics. Based on clinical and sociodemographic variables and questionnaire 
responses, 53 'known-groups' that were expected to differ were formed, e.g. females vs males.  
The EF10 and EF4 were first independently compared within this known-group, e.g. EF10 score 
of females vs EF10 score of males.  When these differences were significant, the RV of EF10 
compared to EF4 was calculated. 
Results: 1028 patients (57% lung, 43% colorectal cancer) participated. Forty-five of the 53 
known-groups comparisons were significantly different and were used for calculating the RV. In 
41 of 45 (91%) comparisons, the RV was >1, meaning that EF10 had a higher RV than EF4. The 
mean RV of EF10 compared to EF4 was 1.41, indicating superior statistical power of EF10 to 
detect differences in EF. 
Conclusions: Compared to EF4, EF10 shows superior power, allowing a 20-34% smaller sample 
size without reducing power, when used as a primary outcome measure.  
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HIGHLIGHTS 
 
i. What is already known about the topic?  
Computerized adaptive testing is a relatively new technique that enables more efficient 
data-collection by questionnaires. The amount and type of questions presented are 
selected according to the participant’s previous responses. They are based on so-called 
item-banks. The European Organisation for Research and Treatment of Cancer Quality of 
Life Group has developed an item bank for emotional functioning, one of its key domains. 
ii. What does the paper add to existing knowledge?  
To date, the emotional functioning item bank has been solely tested in the dataset that was 
used for its development. This study is the first to test the customized short-form in an 
external, independent and international dataset.  
iii. What insights does the paper provide for informing health care-related decision making? 
The customized EF10 short-form shows superior power compared to the commonly used 
QLQ-C30 4-item emotional functioning scale (EF4). This allows for a 20-34% smaller 
sample size without reducing power, when used as a primary outcome measure.  
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INTRODUCTION 
Assessing quality of life of patients with cancer is common practice in clinical trials and is 
strongly suggested as a screening instrument for detecting distress and improving care [1,2]. 
Commonly used questionnaires often lack precision [3,4] and may have problems with floor- 
and/or ceiling-effects, limiting their ability to detect differences between groups and change over 
time.  
Computerized adaptive testing (CAT) is a relatively new technique that enables more 
efficient data-collection of e.g., patient-reported outcomes. The content and the number of 
questions presented are selected according to the participant’s previous responses, i.e. they are 
restricted to those relevant to that specific participant [5,6]. For example, if a participant’s 
responses indicate severe emotional problems, the next item will be one that is relevant for 
people with such severe problems [6]. The items used in CAT are derived from so-called item 
banks [6]. These items have been calibrated (estimated) to an item response theory (IRT) model 
[7,8], which means that scores based on any subset of the items are comparable [6]. 
Since CAT has a higher validity (i.e. the statistical power) than traditional measures, it has 
the potential to reduce trial sample size requirements without reducing power [6]. Even when it is 
not possible to complete questions on a computer, the item banks underlying CAT can be useful. 
Taking into consideration the participant’s characteristics, such as age or type and stage of 
cancer, relevant items can be selected from the item bank and used in pen and paper 
questionnaires, so-called customized short-forms. 
Currently, several organisations work on the enhancement of clinical outcomes research 
by developing efficient measures of patient-reported outcomes using item banks. In the United 
States, Patient-Reported Outcomes Measurement Information System (PROMIS) has developed 
item banks. In Europe, the European Organisation for Research and Treatment of Cancer 
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(EORTC) Quality of Life Group has developed 14 item banks for each of the  domains 
(excluding overall physical condition/quality of life) covered by their core quality of life 
measure, the QLQ-C30. This includes one of its key domains: emotional functioning (EF) [6,9]. 
Traditionally, emotional functioning is assessed with the QLQ-C30 4-item EF scale (EF4), 
measuring depression, anxiety and general distress [10,11], or with a shortened 2-item version 
(EF2) as included in the QLQ-C15-PAL questionnaire, an abbreviated version of the QLQ-C30 
for use in palliative care [12]. To date, the EF item bank has only been tested in the dataset used 
for its development and no external validation has been performed. This study is the first to test a 
customized 10-item short form (EF10) based on the EORTC EF item bank in an external, 
independent and international dataset. 
Our hypothesis is that the customized EF10 will provide more precise results, i.e. better 
discrimination between groups, and thus higher relative validity (RV) and lower expected sample 
size requirements than the original QLQ-C30 EF scale (EF4). The primary aim is to compare the 
RV, which is also known as the relative efficiency, of the EF10 with the EF4. The secondary 
aims are to compare the RV of the EF10 with that of the EF2 and to compare the RV of the EF4 
with that of the EF2. 
  
METHODS 
Sample 
The ACTION cluster randomized clinical trial investigates an adapted version of the Respecting 
Choices advance care planning program. Patients were recruited in pulmonology and oncology 
departments in hospitals in Belgium, Denmark, Italy, the Netherlands, Slovenia and the United 
Kingdom between June 2015 and May 2017. Patients were invited by their treating healthcare 
professional. The ACTION study protocol has been described elsewhere [13].  
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Eligibility requirements included a histologically verified cancer diagnosis of either lung 
cancer stage III or IV, or colorectal cancer stage IV, being aged at least 18 years and being 
physically and mentally competent to give consent and complete the questionnaire. Patients had 
to have a WHO/ ECOG performance status of 0-3 [14]. Written informed consent was obtained. 
Ethics committees of the participating countries approved the study. 
Patients provided information about their age, gender, living situation and educational 
level. Their healthcare professionals provided clinical information, such as the date of diagnosis, 
current disease stage and current treatment. 
 
Assessment of the relative validity 
Box 1.  Scales for the assessment of emotional functioning. 
The EORTC QLQ-C30 EF scale (EF4) consists of four items asking about feeling tense, 
worrying, feeling depressed and being irritable [11]. The EF4 was scored using sum scoring 
following the EORTC scoring manual [15].  
The two-item EF version in the QLQ-C15-PAL (EF2) consists of the items about feeling 
depressed and feeling tense [12]. The EF2 was scored using an appendix to the EORTC scoring 
manual [16].   
A customized 10-item EF short form (EF10) was composed for the trial, including the original 
four QLQ-C30 items (EF4) and six additional items from the EORTC EF item bank [6,9]. The 
EORTC EF item bank includes 24 items and is based on the response of 1,023 patients from 
different countries. The development of the item bank has been described elsewhere in more 
detail [6]. The items for this study were selected by methodological and clinical experts, based on 
characteristics of the target population, such as age and type of cancer 
[17]. The selection of items based on these population characteristics is aimed at making the  
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Box 1.  Scales for the assessment of emotional functioning (continued).measure more 
applicable for the specific population in this study (i.e. patients with advanced cancer). Based on 
results of observed [6] and simulated data (currently in press) put together, asking less than 5-6 
items might give notable loss in power, while asking more than about 14 items would only give 
negligible gain in power. Hence, 10 items were chosen as a good compromise between response 
burden and optimal measurement precision. The EF10 was scored using the IRT model calibrated 
for the EORTC EF item bank [6]. The complete questionnaire is included in the Supplementary 
Material. All EF items concern the experiences “during the past week” and use a four-point 
response scale ranging from “not at all” to “very much”. 
 
We used the method of known-groups validation to evaluate the RV (i.e., statistical power to 
detect group differences) of the EF10 compared with the EF4 and the EF2 [18]. EF is a multi-
dimensional and complex construct that is influenced by various characteristics on the patient 
level (e.g. gender), clinical level (e.g. type of cancer), coping, satisfaction and experience with 
care, and patient involvement. For each patient characteristic and for each questionnaire item 
(except for the emotional functioning items), participants were divided into 'known groups'; two 
groups based on a priori formulated expectations on differences with regard to EF. For example, 
we hypothesized that patients who felt nauseated would have a worse EF than patients who did 
not feel nauseated. In case of continuous variables, such as age, the median value was used as a 
cut-off for the dichotomization. For example, we hypothesized that older patients would have a 
better EF than younger patients [19]. If the median was similar to the highest or the lowest score, 
and thus no groups could be created based on the median value, we calculated the mean value 
and used it as the cut-off to create two groups. In total, we formed 53 pairs of known-groups for 
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the comparison. The EF10, EF4 and EF2 were then each compared within these known-groups 
(e.g. the EF10 of patients who felt nauseated vs the EF10 of patients who did not feel nauseated).  
We used the two-sample t-test (assuming equal variances) to assess significant differences 
between the known-groups for the comparison. The RV was only calculated when the t-test for at 
least one of the measures being compared (EF10, EF4 or EF2) showed a significant difference 
(p<0.05) [18]. For each comparison the t-statistic was calculated and subsequently squared. The 
ratio (= RV) was calculated for each comparison by using the squared t-statistic of the EF10 as 
the numerator and the squared t-statistic of the EF4 or the EF2 as the denominator [6]. We used 
the EF10 as the numerator as we wanted to evaluate the potential gain (or loss) in measurement 
precision and power using the customized EF scale (EF10) compared to the two existing scales 
(EF4 and EF2). Hence, RV>1 would confirm the expectation that EF10 is the more precise 
measure. The mean RV across all characteristics or variables was calculated with a bootstrap 
based 95% confidence interval [20].  A mean RV above 1 indicates that the EF10 has higher RV 
than the EF4 or the EF2. With increasing RV, one can expect more power gained by using the 
EF10. Based on the mean RV we estimated the potential savings in sample size requirements 
using the EF10 compared with using  the EF4 or  the EF2 [21].  
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Box 2.  Example for the translation of the relative validity into a percentage of sample  
size reduction. 
Since the RV is calculated as 𝑅𝑅𝑅𝑅 =  𝑡𝑡2(𝐸𝐸𝐸𝐸10)
𝑡𝑡2(𝐸𝐸𝐸𝐸4) , if RV=1.21 for the E10 vs the EF4, it means that the 
t-test for the EF10 was (√1.21 = 1.1) 1.1 times that of the EF4, or equivalent with 𝑆𝑆𝑆𝑆(𝐸𝐸𝐸𝐸10) = 𝑆𝑆𝑆𝑆(𝐸𝐸𝐸𝐸4)
1.1 . We used this SD-ratio to calculate an estimate of the required sample for the EF10 
compared to the EF4. As an example, if the EF4 with N=128 had power=80% at 𝛼𝛼=5% to detect 
a specific difference, then it can be calculated from the SD-ratio using standard sample size 
calculations that the EF10 would need N=106 to obtain the same power, or  106
128
= 83% of the 
sample for  the EF4.  
We used power=80%, 𝛼𝛼=5% and effect size (ES)=0.5 in the calculations. The expected 
savings for any combination of power and ES will be similar to those presented here, except in 
very extreme cases with very low power or large ES. 
 
Known-group comparisons 
The known-group comparisons were based on the following measures and characteristics: 
 
Sociodemographic and clinical characteristics  
Patients provided information about their age, gender, marital status, whether they had children 
or not, educational level and religiosity. Their healthcare professionals provided clinical 
background information on the type and current stage of the disease and the time since diagnosis 
of both the primary tumor and the current stage of the disease. Additionally, they indicated 
whether the patient received chemotherapy. 
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Quality of life and symptoms 
The EORTC QLQ-C15-PAL, an abbreviated version of the EORTC QLQ-C30 for palliative care, 
was used to measure patients’ quality of life and symptoms [12]. Fourteen items use a four-point 
response scale, ranging from “not at all” to “very much”.  The final and 15th item concerns a 
rating of the overall quality of life during the past week, with response options on a 7-point scale 
ranging from 1 “very poor” to 7 “excellent”. 
 
Coping 
Patients completed three scales, i.e. problem-focused coping, acceptance and avoidance (denial), 
of the brief COPE [22,23]. The twelve questions have a four-point response scale. 
  
Satisfaction with care 
Items from the EORTC IN-PATSAT were used to assess patients’ satisfaction with care, their 
appraisal of hospital doctors and nurses and aspects of care organization and services [24]. The 
questions have a five-point response scale. 
 
Experience of cancer care 
The “Assessment of Patients’ Experience of Cancer Care” (APECC) assesses patients’ 
perceptions of the quality of their cancer care [25]. In order to assess medical decision-making of 
the treatment and care, we selected five items measuring the quality of the medical decision-
making. Responses are given on a five-point scale. 
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Patient involvement 
We developed four questions on patient involvement in treatment and care and the awareness of 
relatives and physicians of the patients’ wishes and preferences, which can be answered on a 
five-point scale.  
 
RESULTS 
Patient characteristics  
Characteristics of the 1,028 participants in the study are presented in Table 1. The majority of the 
sample was male (60%), married (70%) and living in a private household (95%). Most patients 
had lung cancer stage IV (45%) or colorectal cancer stage IV (29%). The majority had a WHO 
performance status of 1 (52%). 
 
Relative validity 
The results of the known-group comparisons of the three scales (EF10, EF4, EF2) are 
summarized in Table 2. The table shows the t-statistics and the RV per known-group comparison 
as well as the mean RV for the comparisons of the EF10 with the EF4, the EF10 with the EF2 
and the EF4 with the EF2, respectively. 
Of the 53 pairs of known-groups considering the EF10 and the EF4, 45 showed a 
statistically significant difference for at least one of the two measures. For these 45 pairs we 
calculated the RV for the EF10 compared with the EF4 and found that RV ranged from 0.47 to 
3.71. In 41 out of the 45 (91%) comparisons, the RV was above 1, indicating that the EF10 had a 
higher RV than the EF4. The mean RV for the comparison of the EF10 with the EF4 was 1.41 
with a bootstrap based 95% confidence interval of 1.28-1.57. Transforming this confidence 
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interval to sample size requirements resulted in a 20%-34% reduction in sample size without loss 
of power. 
When calculating the RV of the EF10 in comparison with the EF2 we found significant 
differences in emotional functioning in 45 of 53 known-group comparisons. 44 of these 45 
comparisons were also significant when comparing the EF10 with the EF4. The RV was 
calculated for these 45 pairs and the EF10 had a higher RV than the EF2 in 40 out of 45 (89%) 
significant comparisons. The mean RV for the EF10 compared with the EF2 was 1.74 (95% CI 
1.48-2.10). This would allow for a 31%-52% reduction in sample size when using the EF10 
instead of the EF2, without loss of power. 
Comparison of the EF4 with the EF2 revealed higher RV of the EF4 in 36 out of 45 (80%) 
significant comparisons. These 45 comparisons differed from the previous comparisons (Table 
2). The mean RV for the comparison of the EF4 with the EF2 was 1.16 (95% CI 1.11-1.26). 
Based on this confidence interval, using the EF4 instead of the EF2 would allow for a 9%-20% 
reduction in sample size without loss of power. 
 
DISCUSSION 
One of the most powerful implications of using CAT is the more precise and efficient estimate of 
a patient’s quality of life by tailoring the items to the patient’s individual characteristics. The aim 
of this study was to compare the RV of the customized EF10 with the original validated EF4 
using the method of known-groups comparison. 
The results of the study confirm our hypothesis that the EF10 has a better RV compared 
with the EF4 and the EF2. This means that the EF10 has superior power to detect differences 
between groups which allows for a smaller sample size to detect differences without reducing 
power. Ninety-one percent of the known-group comparisons indicated higher RV of the EF10 
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compared to the EF4, with an average RV of 1.41. This allows for a smaller sample size of about 
20-34% when using the EF10 instead of the EF4. This indicates that clinical trials having EF as 
primary outcome and using the EF10 instead of the EF4 scale of the QLQ-C30 can be carried out 
with considerably smaller sample sizes without loss of power.  
The EF10 had a higher RV in 89% of the comparisons with the EF2. We also found that 
the EF4 had a higher RV than the EF2. Although this finding was expected and hypothesized 
when the EF2 was developed 11 years ago [12,26], it had not been confirmed empirically. 
Mapping the quality of life of patients is important for the improvement of care and to 
inform treatment decisions. Quality of life is often an important outcome measure in randomized 
clinical trials and observational studies. The savings in sample size that can be obtained by using 
the customized short-form EF10 are particularly important when the study concerns a vulnerable 
group of patients, such as patients with advanced cancer, as the reduced required sample sizes can 
address the often-encountered problems with reaching target numbers in studies. Many palliative 
care trials have failed due to problems with recruitment [27,28]. An additional benefit is that 
when fewer study participants are required while maintaining the same power, innovative 
findings may become ready for implementation sooner. 
Using a customized short-form has many benefits, yet it comes with the costs of the 
complex development (e.g. the creation of an item-bank or the selection of items based on the 
samples’ characteristics). Besides, while the items might lead to less missing values, since the 
questions are more applicable to the respondents’ situation, the questionnaires tend to be 
somewhat longer, which is adding some burden to respondents. Therefore, as is generally the 
case in patient-reported outcome assessments, it is important to weigh the practical gain (i.e. 
increased power) of a longer, more precise measure against minimizing the burden to 
respondents. Note that we aimed here to improve measurement precision by adding relevant 
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items, but customized short forms can also be used to form shorter measures if e.g. the minimum 
response burden has priority. 
The EORTC CAT has been designed for the international use in patients with cancer and 
we tested it for the first time in a large sample of patients with advanced cancer in various 
European countries. This makes generalizability of the results possible. Another strength of this 
study was the high number of known-group comparisons (53 pairs, of which 45 were significant), 
which makes the findings robust and reduces the risk that conclusions are influenced by chance 
findings. Additionally, we calculated the RV only when the t-test for at least one of the measures 
being compared (EF10, EF4 or EF2) showed a significant difference.  
 While this study used cross-sectional data, extending and replicating our approach based 
on longitudinal ACTION data will be possible in due course. We used the EORTC item bank on 
emotional functioning, which has the structure of the original QLQ-C30 scale with respect to the 
number of response options and phrasing of items. One might consider this a limitation in 
comparison to e.g. the PROMIS item banks that were developed from scratch, while aiming for 
the optimal way to address concepts. However, due to its design (being a new measurement 
system) the PROMIS item banks do not allow comparison to a pre-existing, validated instrument 
measuring exactly the same construct, using the same wording. Instead they need to compare the 
RV to alternative instruments measuring a similar construct. In our study we were able to assess 
the RV of the EF10 to a validated instrument measuring exactly the same construct. 
 
Conclusions 
We found that the customized EF10 based on the EORTC CAT item bank performs better than 
the EF4 in detecting differences in emotional functioning between groups of patients with 
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advanced cancer. Compared to the EF4, the EF10 showed superior power, allowing a 20-34% 
smaller sample size without reducing power, when used as a primary outcome measure.   
21 
  
REFERENCES  
1. Zebrack B, Burg MA, Vaitones V. Distress screening: an opportunity for enhancing 
quality cancer care and promoting the oncology social work profession. J Psychosoc 
Oncol. 2012;30(6):615-624. 
2. Turk DC, Dworkin RH, Allen RR, et al. Core outcome domains for chronic pain clinical 
trials: IMMPACT recommendations. Pain. 2003;106(3):337-345. 
3. Smith AB, Wright EP, Rush R, Stark DP, Velikova G, Selby PJ. Rasch analysis of the 
dimensional structure of the Hospital Anxiety and Depression Scale. Psychooncology. 
2006;15(9):817-827. 
4. Cull A, Gould A, House A, et al. Validating automated screening for psychological 
distress by means of computer touchscreens for use in routine oncology practice. Br J 
Cancer. 2001;85(12):1842-1849. 
5. Wainer H. Computerized adaptive testing: a primer. 2nd ed. Mahwah, NJ: Lawrence 
Erlbaum Associates, Inc.; 2000. 
6. Petersen MA, Gamper EM, Costantini A, et al. An emotional functioning item bank of 24 
items for computerized adaptive testing (CAT) was established. J Clin Epidemiol. 
2016;70:90-100. 
7. Hambleton RK, Swaminathan H, Rogers HK. Fundamentals of item response theory. 
Newbury Park: Sage Publications, Inc; 1991. 
8. van der Linden WK, Hambleton RK. Handbook of modern item response theory. Berlin: 
Springer-Verlag; 1997. 
9. Gamper EM, Groenvold M, Petersen MA, et al. The EORTC emotional functioning 
computerized adaptive test: phases I-III of a cross-cultural item bank development. 
Psychooncology. 2014;23(4):397-403. 
22 
  
10. Fayers P, Bottomley A, Unit obotEQoLGaotQoL. Quality of life research within the 
EORTC - the EORTC QLQ-C30. Eur J Cancer. 2002;38:S125-S133. 
11. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research 
and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International 
Clinical Trials in Oncology. J Natl Cancer Inst. 1993;85:365-376. 
12. Groenvold M, Petersen MA, Aaronson NK, et al. The development of the EORTC QLQ-
C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer. 
2006;42(1):55-64. 
13. Rietjens JA, Korfage IJ, Dunleavy L, et al. Advance care planning--a multi-centre cluster 
randomised clinical trial: the research protocol of the ACTION study. BMC Cancer. 
2016;16:264. 
14. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern 
Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-655. 
15. Fayers PM, Aaronson NK, Bjordal K, et al. The EORTC QLQ-C30 Scoring Manual (3rd 
Edition) Brussels: European Organisation for Research and Treatment of Cancer; 2001. 
16. Groenvold M, Petersen MA, Group obotEQoL. Addendum to the EORTC QLQ-C30 
Scoring Manual: Scoring of the EORTC QLQ-C15-PAL 2006. 
17. Scott NW, Fayers PM, Aaronson NK, et al. EORTC QLQ-C30 Reference Values. 2008. 
18. Fayers PM, Machin D. Quality of Life - The assessment, analysis and reporting of 
patient-reported outcomes (3rd Edition). Chichester, West Sussex: John Wiley & Sons, 
Ltd. ; 2016. 
19. Wenzel LB, Fairclough DL, Brady MJ, et al. Age-related differences in the quality of life 
of breast carcinoma patients after treatment. Cancer. 1999;86(9):1768-1774. 
23 
  
20. Deng N, Allison JJ, Fang HJ, Ash AS, Jr. WJ. Using the bootstrap to establish statistical 
significance for relative validity comparisons among patient-reported outcome measures. 
Health QuL Life Outcomes. 2013;11(89). 
21. Petersen MA, Aaronson NK, Arraras JI, et al. The EORTC computer-adaptive tests 
measuring physical functioning and fatigue exhibited high levels of measurement 
precision and efficiency. J Clin Epidemiol. 2013;66(3):330-339. 
22. Carver CS, Scheier MF, Weintraub JK. Assessing coping strategies: a theoretically based 
approach. J Pers Soc Psychol. 1989;56(2):267-283. 
23. Carver CS. You want to measure coping but your protocol's too long: Consider the Brief 
COPE. Int J Behav Med. 1997;4:92-100. 
24. Brédart A, Bottomley A, Blazeby JM, et al. An international prospective study of the 
EORTC cancer in-patient satisfacation with care measure (EORTC IN-PATSAT32). Eur 
J Cancer. 2005;41(14):2120-2131. 
25. Arora NK, Reeve BB, Hays RD, Clauser SB, Oakley-Girvan I. Assessment of quality of 
cancer-related follow-up care from the cancer survivor's perspective. J Clin Oncol. 
2011;29(10):1280-1289. 
26. Bjorner JB, Petersen MA, Groenvold M, et al. Use of item response theory to develop a 
shortened version of the EORTC QLQ-C30 emotional functioning scale. Qual Life Res. 
2004;13(10):1683-1697. 
27. Buss MK, Arnold RM. Challenges in palliative care research: one experience. J Palliat 
Med. 2004;7(3):405-407. 
24 
  
28. Ewing G, Rogers M, Barclay S, McCabe J, Martin A, Todd C. Recruiting patients into a 
primary care based study of palliative care: why is it so difficult? . Palliat Med. 
2004;18(5):452-459. 
 
25 
  
TABLES 
Table I.  Sociodemographic and clinical characteristics of the study sample (N = 1,028) 
 
Characteristic1  
Age, mean (SD) 
Range 
65.91 (9.85) 
18, 91 
Gender, n (%)  
Male 592 (60.2) 
Country of residence, n (%)  
Belgium 180 (18.1)  
Denmark 134 (13.6) 
Italy 147 (14.9) 
The Netherlands 229 (23.2) 
Slovenia 74 (7.5) 
The United Kingdom 218 (22.1) 
Civil status, n (%)   
Married, civil partnership 683 (70.1) 
Divorced, separated 110 (11.3) 
Widowed 96 (9.8) 
Unmarried 86 (8.8) 
Living with partner, n (%) 717 (74.1) 
Living conditions  
Private household 915 (94.4) 
Institutionary care 6 (0.6) 
Other 48 (5.0) 
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Having children, n (%) 848 (86.8) 
Education  
Years of education, mean (SD) 
Range  
13.17 (4.59) 
0, 45 
Interquartile range 10.0, 13.0, 16.0 
Religion, n (%)  
Religious 491 (50.5) 
Not-religious 353 (36.3) 
Prefers not to specify 128 (13.2) 
Ethnicity, n (%)  
No ethnic minority 943 (99.0) 
Cancer type and current stage, n (%)  
Lung cancer (stage III or IV) 534 (57.6) 
Colorectal cancer (stage IV or metachronous 
metastases)  
393 (42.4) 
Time since diagnosis in years, mean (SD) 
Range 
1.4 (1.82) 
0, 11 
Time since diagnosis of current stage in years, mean 
(SD) 
Range 
0.85 (1.16) 
0, 9.69 
Current treatment, n (%)2  
Chemotherapy 301 (29.3) 
Targeted therapy 866 (84.2) 
Immunotherapy 897 (87.3) 
Radiotherapy 921 (89.6) 
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WHO performance status, n (%)   
0: fully active  318 (34.4) 
1: restricted in physically strenuous activity  486 (52.6) 
2: ambulatory and capable of all selfcare 107 (11.6) 
3: capable of only limited selfcare 13 (1.4) 
NOTE:  
1 Missing: Age (n=11), Gender (n=6), Country of residence (n=7), Civil status (n=14), Living 
with partner (n=21), Living conditions (n=20), Having children (n=12), Education (n=130), 
Religion (n=17), Ethnicity (n=36), Cancer type and stage (n=62), WHO performance status 
(n=65) 
2 Several options may apply. 
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Table 2. Relative validity of the three scales to assess Emotional Functioning.   
Scale EF10 
t-statistic 
EF4 
t-statistic 
EF2 
t-statistic 
Relative  
validity 
EF10/EF4 
Relative 
validity 
EF10/EF2 
Relative  
validity 
EF4/EF2 
 
Patient characteristics      
Age1 1.43 2.09 1.54 0.47 - 1.84 
Gender 3.90 3.72 4.31 1.10 0.82 0.75 
Spouse2 - - - - - - 
Children yes/ no2 - - - - - - 
Education 2.06 3.01 3.02 0.47 0.46 0.99 
Religious -4.47 
 
-4.43 -3.81 1.02 1.38 1.35 
Lung cancer vs colorectal cancer -3.04 -2.94 -2.86 1.07 1.13 1.06 
Stage2 - - - - - - 
Chemotherapy yes/ no2 - - - - - - 
Time since diagnosis 2.99 2.27 2.16 1.73 1.92 1.11 
Time in stage 3.43 2.88 2.51 1.41 1.86 1.31 
WHO status 4.69 3.95 4.07 1.41 1.33 0.94 
Quality of life (EORTC QLQ-C15-PAL) 
 
Physical functioning: trouble taking a short walk -10.69 -9.07 -8.19 1.39 1.70 1.23 
Physical functioning: need to stay in bed or a chair  -8.53 -6.63 -6.43 1.65 1.76 1.06 
Physical functioning: help with eating, dressing, washing  -7.34 -7.00 -6.69 1.10 1.20 1.09 
Dyspnea -8.65 -7.41 -6.66 1.36 1.68 1.24 
Pain -8.21 -8.12 -7.28 1.02 1.27 1.24 
Insomnia -8.29 -7.95 -7.76 1.09 1.14 1.05 
Fatigue -13.70 -11.04 -10.54 1.54 1.69 1.10 
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Lack of appetite -11.78 -9.82 -9.29 1.44 1.61 1.12 
Nausea -10.25 -9.10 -8.77 1.27 1.37 1.08 
Constipation -5.63 -5.21 -5.54 1.17 1.03 0.88 
Tiredness  -14.88 -13.20 -13.46 1.27 1.22 0.96 
Interference due to pain -11.31 -10.65 -10.42 1.13 1.18 1.04 
Overall quality of life 
 
15.41 12.80 12.51 1.45 1.52 1.05 
Coping (COPE)      
Active: efforts on doing something about it 3.20 2.91 3.01 1.21 1.13 0.94 
Acceptance: accepting the reality  5.44 4.65 4.47 1.37 1.48 1.08 
Planning: coming up with a strategy 2.66 2.99 3.72 0.79 0.51 0.65 
Active: taking action  3.34 2.92 2.90 1.31 1.33 1.01 
Denial: acting as though it hasn’t happened2 - - - - - - 
Denial: saying “this isn’t real” -3.08 -3.19 -3.42 0.94 
 
0.81 0.87 
Denial: pretending this hasn’t happened 3 -1.84 -1.88 -1.98 - 0.86 0.90 
Acceptance: learning to live with it 8.15 6.40 6.13 1.62 
 
1.77 1.09 
Planning: thinking about what steps to take2 - - - - - - 
Denial: refusing to believe that it has happened -3.36 -2.78 -2.73 1.46 1.51 1.04 
Acceptance: getting used to the idea 4.94 4.28 3.51 1.33 1.98 1.48 
Acceptance: accepting that it has happened 4.43 3.92 3.43 1.28 1.67 1.30 
Satisfaction with care (IN-PATSAT) 
Information about illness (by doctors) 5.50 4.42 3.62 1.55 2.31 1.49 
Information about medical tests (by doctors) 5.90 4.53 3.94 1.70 2.24 1.32 
Information about treatment (by doctors) 
 
5.82 4.90 3.97 1.41 2.15 1.52 
Information about medical tests (by nurses) 5.79 4.88 4.68 1.41 1.53 1.09 
Information about care (by nurses) 5.46 4.14 3.68 1.74 2.20 1.26 
Information about treatment (by nurses) 5.94 4.83 4.27 1.51 1.93 1.28 
General rating of received care 6.71 4.95 4.39 1.84 2.34 1.27 
Experience of cancer care (APECC) 
Detailed discussions 6.88 5.80 5.09 1.41 1.83 1.30 
Concerns/ questions 6.73 5.07 4.78 1.76 1.98 1.13 
Preferred option 
 
7.31 6.32 5.58 1.34 1.72 1.28 
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NOTE:  
1 not significant for the comparison of E10 with E2 (p>0.05) 
2 not significant for any comparison (p>0.05) 
3 not significant for the comparison of E10 with E4 (p>0.05) 
4 not significant for the comparison of E4 with E2 (p>0.05) 
Work out differences 6.24 5.29 4.52 1.39 1.90 1.37 
Responsible for final decision 5.34 4.36 3.58 1.50 2.22 1.48 
Patient Involvement  
Friends are aware of wishes4 3.40 1.77 1.20 3.71 8.03 - 
Doctors are aware of wishes1 - - - - - - 
Involvement as preferred 5.16 3.79 3.61 1.85 2.04 1.10 
 
 
Great influence on care 3.65 2.26 1.97 2.60 3.43 1.32 
Mean ratio    1.41 1.74 1.16 
95% CI    1.28-1.57 1.48-2.10 1.11-1.26 
